IMNM: Cup Handle detected on 7 Aug 2026

A cup-handle pattern is forming in IMNM with current price at $25.82, positioned above key resistance at $24.39. The pattern quality scores reveal a moderately strong setup: structure score of 13.5/15, volume of 11.0/12, and breakout score of 12.0/13 for an overall score of 79.5/98. The stock's RSI sits at 72.35, indicating overbought conditions. Volume ratio of 0.79 shows below-average volume relative to the 20-day average (832,002 vs. 1,049,793 shares). A concurrent higher_lows_volume_spike pattern formed on July 2, 2026 with moderate strength. The cup structure suggests accumulation with the handle forming in the most recent trading days.

Immunome is a clinical-stage targeted oncology company focused on developing first-in-class targeted cancer therapies. In April 2026, the company received Investigational New Drug (IND) clearance for IM-1617, a potential first-in-class solid tumor antibody-drug conjugate (ADC). An NDA submission for varegacestat reflects commitment to desmoid tumor treatment, with detailed Phase 3 RINGSIDE data selected for oral presentation at ASCO. On July 20, 2026, Immunome announced the first patient dosed in a Phase 1 trial evaluating IM-3050, an FAP-targeted radioligand therapy. The stock received buy ratings from Wedbush and Craig-Hallum in June 2026. This pipeline progression and positive analyst sentiment are driving momentum into the pattern formation.

A successful breakout above $24.39 resistance would target the conservative measure move of $27.77, representing a 7.5% advance. The win probability score of 54.49% indicates coin-flip odds—slightly better than random. Volume confirmation is critical; the setup needs sustaining volume above 1.05 million shares to validate the breakout, as current volume at 0.79 ratio signals weakening participation. Pattern invalidation occurs below $21.61 key support, a 16.3% downside risk. The cup-handle formation suggests a breakout could drive momentum higher if volume confirms; failure to hold above resistance turns the pattern suspect.

RSI at 72.35 signals overbought conditions, elevating near-term pullback risk despite bullish pattern structure. Volume has been contracting relative to the 20-day average (0.79 ratio), suggesting weakening conviction in the uptrend—a red flag for pattern sustainability. An earnings date is estimated for August 4, 2026, creating imminent event risk that could trigger volatility disrupting the pattern or accelerating a breakout. Beta of 0.74 provides some defensive characteristics, but clinical-stage biotech typically carries binary event risk around trial data and regulatory decisions. The company's pipeline milestones and catalysts mean any negative trial updates or regulatory setbacks could swiftly invalidate the bullish setup. Recent insider equity grants (June 2026) at $20.78 suggest equity positioning, though not necessarily warning of insiders selling.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.